行情

ATOS

ATOS

Atossa Genetics
NASDAQ

实时行情|Nasdaq Last Sale

1.370
-0.010
-0.72%
已收盘, 16:00 12/06 EST
开盘
1.400
昨收
1.380
最高
1.450
最低
1.370
成交量
4.38万
成交额
--
52周最高
7.39
52周最低
0.8000
市值
1,250.94万
市盈率(TTM)
-0.6399
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ATOS 新闻

  • Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019
  • GlobeNewswire.1天前
  • 美农场破产量飙升24%创6年新高 农业危机“在路上”?
  • 第一财经.3天前
  • 资金流向复盘 | 南下资金今日净流入港股超28亿港元
  • 华盛通.3天前
  • 瑞银:欧央行利率会议中性看待欧元 明年有望徐徐上涨
  • 新浪财经综合.3天前

更多

所属板块

先进医疗设备和技术
+0.69%
医疗设备和用品
+0.64%

热门股票

名称
价格
涨跌幅

ATOS 简况

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.
展开

Webull提供Atossa Genetics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。